Human Genome Sciences (NASDAQ:HGSI.DL)

CAPS Rating: No stars

The drug development company with three products advancing into late-stage clinical development: Albuferon(r) for chronic hepatitis C, LymphoStat-B(r) for systemic lupus erythematosus, and ABthraxtm for anthrax disease.


Player Avatar Redhat821 (< 20) Submitted: 12/13/2009 2:05:34 PM : Outperform Start Price: $28.08 HGSI.DL Score: -71.43

Not investing in HGSI is like throwing money into the trash. And shorting this stock is like stepping in front of a freight train... Ouch and bankruptcy rolled into one.

Why HGSI will be the next large cap biotech company if it's not bought out:

1. Benlysta (HGSI) for Lupus is significantly underappreciated. 5M WW suffer from Lupus. Last approved therapy was in the 1960s - steroids (nasty side effects and not very effective). Benlysta will have market exclusivity for quite sometime (nothing in the near term in pipelines for other companies). Pricing for Benlysta is estimated to be around $30K. You can do the math on the market potential.

2. Benlysta works in other autoimmune diseases - MS and RA to name a few. Any additional indication would be gravy, since you can leverage the same sales force (same doctors targeted).

3. Albuferon for HEP C for free.

4. Cancer pipeline for free.

5. Almost every large pharma/biotech company is calling HGSI to find out their price for a takeout. Large pharma.biotech companies are suffering from depleted pipelines, facing a huge patent cliff on their current existing drugs/biologics, and have lots of cash on hand. HGSI is a no brainer.

Report this Post 2 Replies
Member Avatar Redhat821 (< 20) Submitted: 12/13/2009 2:12:26 PM
Recs: 0

6. I completely forgot to mention that Benlysta has a pristine safety profile and has excellent data regarding the reductionof severe flares.

Long live HGSI!

Member Avatar NASDAQCZAR (65.62) Submitted: 1/10/2010 4:20:35 AM
Recs: 0

fda will never approve any of hgsi junk compounds, lupus will need 10 years of data and multiple phase 3 trials, the anthrax drug was rejected in november by the fda it's never been tested on humans perhaps you would like to volunteer???? monkeys lolllllll comical the fda isn't stupid and hgsi has zero prospects for fda approval in the next 5 years atleast hgsi is headed back to $2 eom

Featured Broker Partners